$9.60 0.26 (+2.77%)
11/25/2009 12:19 PM

Seattle Genetics, Inc. (SGEN)

CAPS Rating: 4 out of 5

A biotechnology company, which develops monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases.

Featured Broker Partners